Adaptive Biotechnologies vs Moolec Science SA
Moolec Science SA is the larger business, with $334m of revenue in fiscal 2025 against $277m for Adaptive Biotechnologies (1.2 times as much). Adaptive Biotechnologies grew faster (54.8% against -28.5%). Adaptive Biotechnologies kept more of each dollar of sales as profit: a net margin of -21.5% against -33.4%.
| Latest fiscal year | Adaptive BiotechnologiesADPT, 2025 | Moolec Science SAMLEC, 2025 |
|---|---|---|
| Revenue | $277m | $334m |
| Revenue growth | 54.8% | -28.5% |
| Net income | −$59.5m | −$111m |
| Operating margin | -20.6% | -31.2% |
| Net margin | -21.5% | -33.4% |
| Return on equity | -28.2% | — |
| Free cash flow | −$48.9m | −$2.0m |
| Cash | $70.5m | $767,919 |
| Total debt | $131m | $1.3m |
| Debt to equity | 60.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 624 | — |
| Market value | $4.10bn | $9.3m |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | — |
| Insider trades, 12 months | 0 buys, 168 sales | 0 buys, 0 sales |